Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02686268 · ClinicalTrials.gov registry record
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 128
- Enrollment target
NCT02686268 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 128 participants.
The verdict
NCT02686268 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 128 participants
- Enrollment target
Study Summary
This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene. This mutation is the most common genetic cause of ALS, and is present in 40% of ALS patients with a family history of ALS and 5-10% of ALS patients without a family history of ALS.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-10-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02686268
The ClinicalTrials.gov registry entry for NCT02686268 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02686268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02686268 about?
NCT02686268 is a clinical study titled "Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS". This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene. This mutation is the most common genetic cause of ALS, and is present in 40% of ALS patients with a family history of ALS and ...
What is the current status of trial NCT02686268?
This trial is currently completed. The enrollment target is 128 participants. The study started on 2015-02. Estimated completion is 2018-10-02.
Who is sponsoring clinical trial NCT02686268?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.